{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:01:21Z","timestamp":1790744481012,"version":"4.1.0"},"reference-count":99,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T00:00:00Z","timestamp":1559347200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004348","name":"Stockholms L\u00e4ns Landsting","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004348","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004200","name":"Stiftelsen Olle Engkvist Byggm\u00e4stare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004200","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Gastroenterology"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1016\/j.bpg.2019.101635","type":"journal-article","created":{"date-parts":[[2019,7,22]],"date-time":"2019-07-22T08:32:41Z","timestamp":1563784361000},"page":"101635","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"special_numbering":"C","title":["Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome"],"prefix":"10.1016","volume":"40-41","author":[{"given":"Greger","family":"Lindberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpg.2019.101635_bib1","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1053\/j.gastro.2016.02.031","article-title":"Bowel disorders","volume":"150","author":"Lacy","year":"2016","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib2","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1053\/j.gastro.2014.02.054","article-title":"Loss-of-function of the voltage-gated sodium channel NaV1.5 (channelopathies) in patients with irritable bowel syndrome","volume":"146","author":"Beyder","year":"2014","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib3","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1136\/gutjnl-2016-312456","article-title":"Functional variants in the sucrase-isomaltase gene associate with increased risk of irritable bowel syndrome","volume":"67","author":"Henstr\u00f6m","year":"2018","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.101635_bib4","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/0016-5085(95)90373-9","article-title":"Irritable bowel syndrome and dyspepsia in the general population: overlap and lack of stability over time","volume":"109","author":"Agr\u00e9us","year":"1995","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib5","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1046\/j.1365-2036.2003.01456.x","article-title":"The prevalence, patterns and impact of irritable bowel syndrome: an international survey of 40,000 subjects","volume":"17","author":"Hungin","year":"2003","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.101635_bib6","doi-asserted-by":"crossref","first-page":"132","DOI":"10.3109\/02813432.2013.811949","article-title":"Low prevalence of irritable bowel syndrome in primary health care in four Swedish counties","volume":"31","author":"Waehrens","year":"2013","journal-title":"Scand J Prim Health Care"},{"key":"10.1016\/j.bpg.2019.101635_bib7","first-page":"107","article-title":"Pseudo-obstruction","volume":"3","author":"Christensen","year":"1990","journal-title":"Gastroenterol Int"},{"issue":"Suppl","key":"10.1016\/j.bpg.2019.101635_bib8","first-page":"S1","article-title":"Disorders of gastrointestinal motility: towards a new classification","volume":"17","author":"Wingate","year":"2002","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib9","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1080\/00365520902839642","article-title":"Clinical features and long-term survival in chronic intestinal pseudo-obstruction and enteric dysmotility","volume":"44","author":"Lindberg","year":"2009","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib10","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1136\/gut.2008.148296","article-title":"Full-thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility","volume":"58","author":"Lindberg","year":"2009","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.101635_bib11","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1111\/j.1365-2982.2011.01783.x","article-title":"Patient-reported outcomes and gut dysmotility in functional gastrointestinal disorders","volume":"23","author":"Cogliandro","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bpg.2019.101635_bib12","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1093\/oxfordjournals.aje.a117548","article-title":"Irritable bowel syndrome in a community: symptom subgroups, risk factors, and health care utilization","volume":"142","author":"Talley","year":"1995","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.bpg.2019.101635_bib13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.mcna.2018.08.006","article-title":"Irritable bowel syndrome: what treatments really work","volume":"103","author":"Alammar","year":"2019","journal-title":"Med Clin N Am"},{"key":"10.1016\/j.bpg.2019.101635_bib14","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/j.mayocp.2018.04.032","article-title":"Management options for irritable bowel syndrome","volume":"93","author":"Camilleri","year":"2018","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.bpg.2019.101635_bib15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1586\/17474124.2016.1158099","article-title":"Novel pharmacological therapies for irritable bowel syndrome","volume":"10","author":"Corsetti","year":"2016","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib16","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1038\/ajg.2010.480","article-title":"Physical activity improves symptoms in irritable bowel syndrome: a randomized controlled trial","volume":"106","author":"Johannesson","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib17","doi-asserted-by":"crossref","first-page":"600","DOI":"10.3748\/wjg.v21.i2.600","article-title":"Intervention to increase physical activity in irritable bowel syndrome shows long-term positive effects","volume":"21","author":"Johannesson","year":"2015","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib18","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1097\/00042737-200012010-00008","article-title":"Patient knowledge and educational needs in irritable bowel syndrome","volume":"12","author":"O'Sullivan","year":"2000","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.cgh.2009.06.025","article-title":"Do we know what patients want? The doctor-patient communication gap in functional gastrointestinal disorders","volume":"7","author":"Collins","year":"2009","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib20","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1111\/j.1471-6712.2010.00855.x","article-title":"Learning to live with irritabel bowel syndrome. The influence of a group-based patient education programme on peoples' ability to manage illness in everyday life","volume":"25","author":"H\u00e5kanson","year":"2011","journal-title":"Scand J Caring Sci"},{"key":"10.1016\/j.bpg.2019.101635_bib21","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1016\/S1542-3565(04)00241-1","article-title":"Effects of multidisciplinary education on outcomes in patients with irritable bowel syndrome","volume":"2","author":"Saito","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib22","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1097\/MEG.0b013e3283333b61","article-title":"Structured patient education is superior to written information in the management of patients with irritable bowel syndrome: a randomized controlled study","volume":"22","author":"Ringstr\u00f6m","year":"2010","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib23","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1136\/gut.2003.037697","article-title":"Food elimination based on IgG antibodies in irritable bowel syndrome: a randomised controlled trial","volume":"53","author":"Atkinson","year":"2004","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.101635_bib24","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1186\/1471-230X-12-166","article-title":"IgG and IgG4 antibodies in subjects with irritable bowel syndrome: a case control study in the general population","volume":"12","author":"Ligaarden","year":"2012","journal-title":"BMC Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib25","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1016\/j.cgh.2008.02.058","article-title":"Dietary triggers of abdominal symptoms in patients with irritable bowel syndrome: randomized placebo-controlled evidence","volume":"6","author":"Shepherd","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib26","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.nut.2017.07.004","article-title":"Low fermentable, oligo-, di-, mono-saccharides and polyol diet in the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"45","author":"Schumann","year":"2018","journal-title":"Nutrition"},{"key":"10.1016\/j.bpg.2019.101635_bib27","doi-asserted-by":"crossref","first-page":"b3154","DOI":"10.1136\/bmj.b3154","article-title":"Soluble or insoluble fibre in irritable bowel syndrome in primary care? Randomised placebo controlled trial","volume":"339","author":"Bijkerk","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.bpg.2019.101635_bib28","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1038\/ajg.2014.195","article-title":"The effect of fiber supplementation on irritable bowel syndrome: a systematic review and meta-analysis","volume":"109","author":"Moayyedi","year":"2014","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/s41395-018-0222-5","article-title":"Effect of antidepressants and psychological therapies in irritable bowel syndrome: an updated systematic review and meta-analysis","volume":"114","author":"Ford","year":"2019","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib30","first-page":"CD003460","article-title":"Bulking agents, antispasmodics and antidepressants for the treatment of irritable bowel syndrome","author":"Ruepert","year":"2011","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpg.2019.101635_bib31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.2147\/CEG.S123621","article-title":"Spotlight on eluxadoline for the treatment of patients with irritable bowel syndrome with diarrhea","volume":"10","author":"Fragkos","year":"2017","journal-title":"Clin Exp Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib32","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.cgh.2007.12.015","article-title":"Effects of 5-hydroxytryptamine (serotonin) type 3 antagonists on symptom relief and constipation in nonconstipated irritable bowel syndrome: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Andresen","year":"2008","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib33","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2165\/11590690-000000000-00000","article-title":"The risk of ischaemic colitis in irritable bowel syndrome patients treated with serotonergic therapies","volume":"34","author":"Lewis","year":"2011","journal-title":"Drug Saf"},{"key":"10.1016\/j.bpg.2019.101635_bib34","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/apt.13227","article-title":"Systematic review with meta-analysis: the prevalence of bile acid malabsorption in the irritable bowel syndrome with diarrhoea","volume":"42","author":"Slattery","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.101635_bib35","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1136\/gutjnl-2013-305965","article-title":"Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS","volume":"64","author":"Bajor","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.101635_bib36","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/apt.13065","article-title":"Effect of colesevelam on faecal bile acids and bowel functions in diarrhoea-predominant irritable bowel syndrome","volume":"41","author":"Camilleri","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.101635_bib37","doi-asserted-by":"crossref","first-page":"3503","DOI":"10.1111\/j.1572-0241.2000.03368.x","article-title":"Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome","volume":"95","author":"Pimentel","year":"2000","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib38","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1111\/j.1572-0241.2008.01785.x","article-title":"Lactulose breath testing does not discriminate patients with irritable bowel syndrome from healthy controls","volume":"103","author":"Bratten","year":"2008","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1136\/gut.2009.205476","article-title":"Combined oro-caecal scintigraphy and lactulose hydrogen breath testing demonstrate that breath testing detects oro-caecal transit, not small intestinal bacterial overgrowth in patients with IBS","volume":"60","author":"Yu","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.101635_bib40","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1111\/apt.15001","article-title":"Systematic review with meta-analysis: the efficacy of prebiotics, probiotics, synbiotics and antibiotics in irritable bowel syndrome","volume":"48","author":"Ford","year":"2018","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.101635_bib41","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1097\/MEG.0000000000000425","article-title":"The role of fiber supplementation in the treatment of irritable bowel syndrome: a systematic review and meta-analysis","volume":"27","author":"Nagarajan","year":"2015","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib42","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/ajg.2013.197","article-title":"Randomized clinical trial: macrogol\/PEG 3350 plus electrolytes for treatment of patients with constipation associated with irritable bowel syndrome","volume":"108","author":"Chapman","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib43","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/tcrm.2007.3.1.107","article-title":"Tegaserod in the treatment of irritable bowel syndrome (IBS) with constipation as the prime symptom","volume":"3","author":"Layer","year":"2007","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.bpg.2019.101635_bib44","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1136\/gut.2010.227132","article-title":"Effect of laxatives and pharmacological therapies in chronic idiopathic constipation: systematic review and meta-analysis","volume":"60","author":"Ford","year":"2011","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.101635_bib45","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1053\/j.gastro.2018.08.021","article-title":"Efficacy of secretagogues in patients with irritable bowel syndrome with constipation: systematic review and network meta-analysis","volume":"155","author":"Black","year":"2018","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib46","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1365-2036.2011.04637.x","article-title":"Review article: the treatment of functional abdominal bloating and distension","volume":"33","author":"Schmulson","year":"2011","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.101635_bib47","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/ajg.2017.41","article-title":"Tenapanor treatment of patients with constipation-predominant irritable bowel syndrome: a phase 2, randomized, placebo-controlled efficacy and safety trial","volume":"112","author":"Chey","year":"2017","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib48","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s10350-003-0016-7","article-title":"Outcome of colectomy for slow-transit constipation in relation to presence of small-bowel dysmotility","volume":"47","author":"Glia","year":"2004","journal-title":"Dis Colon Rectum"},{"key":"10.1016\/j.bpg.2019.101635_bib49","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1111\/nmo.12535","article-title":"Functional gastrointestinal disorders are associated with the joint hypermobility syndrome in secondary care: a case-control study","volume":"27","author":"Fikree","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bpg.2019.101635_bib50","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1111\/nmo.12665","article-title":"Ehlers Danlos syndrome and gastrointestinal manifestations: a 20-year experience at Mayo Clinic","volume":"27","author":"Nelson","year":"2015","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bpg.2019.101635_bib51","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1111\/j.1365-2982.2010.01638.x","article-title":"Familial intestinal degenerative neuropathy associated with chronic intestinal pseudo-obstruction","volume":"23","author":"Ahlfors","year":"2011","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bpg.2019.101635_bib52","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1016\/j.cgh.2006.05.001","article-title":"Clinical, radiologic, and manometric characteristics of chronic intestinal dysmotility: the Stanford experience","volume":"4","author":"Rosa-e-Silva","year":"2006","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib53","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1007\/s00125-016-4199-6","article-title":"Type 1 diabetic patients with peripheral neuropathy have pan-enteric prolongation of gastrointestinal transit times and an altered caecal pH profile","volume":"60","author":"Farmer","year":"2017","journal-title":"Diabetologia"},{"key":"10.1016\/j.bpg.2019.101635_bib54","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1365-2796.1995.tb01196.x","article-title":"Gastrointestinal motility disorders and bacterial overgrowth","volume":"237","author":"Husebye","year":"1995","journal-title":"J\u00a0Intern Med"},{"key":"10.1016\/j.bpg.2019.101635_bib55","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s11894-019-0671-z","article-title":"The spectrum of small intestinal bacterial overgrowth (SIBO)","volume":"21","author":"Quigley","year":"2019","journal-title":"Curr Gastroenterol Rep"},{"key":"10.1016\/j.bpg.2019.101635_bib56","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.cgh.2007.06.013","article-title":"The narcotic bowel syndrome: clinical features, pathophysiology, and management","volume":"5","author":"Grunkemeier","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib57","first-page":"1126","article-title":"New developments in the treatment of opioid-induced gastrointestinal symptoms","volume":"6","author":"Pannemans","year":"2018","journal-title":"U\u00a0Eur Gastroenterol J."},{"key":"10.1016\/j.bpg.2019.101635_bib58","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1111\/nmo.12832","article-title":"Prucalopride induces high-amplitude propagating contractions in the colon of patients with chronic constipation: a randomized study","volume":"28","author":"Miner","year":"2016","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bpg.2019.101635_bib59","first-page":"2696947","article-title":"The effect of prucalopride on small bowel transit time in hospitalized patients undergoing capsule endoscopy","volume":"2017","author":"Alsahafi","year":"2017","journal-title":"Chin J Gastroenterol Hepatol"},{"key":"10.1016\/j.bpg.2019.101635_bib60","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1056\/NEJM199111213252102","article-title":"Effect of octreotide on intestinal motility and bacterial overgrowth in scleroderma","volume":"325","author":"Soudah","year":"1991","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.bpg.2019.101635_bib61","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/BF01300701","article-title":"Erythromycin induces migrating motor complex in human gastrointestinal tract","volume":"31","author":"Tomomasa","year":"1986","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2019.101635_bib62","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3109\/00365521.2012.654402","article-title":"Effect of azithromycin on small bowel motility in patients with gastrointestinal dysmotility","volume":"47","author":"Chini","year":"2012","journal-title":"Scand J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib63","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1016\/j.jpedsurg.2014.09.025","article-title":"Pediatric chronic intestinal pseudo-obstruction is a rare, serious, and intractable disease: a report of a nationwide survey in Japan","volume":"49","author":"Muto","year":"2014","journal-title":"J\u00a0Pediatr Surg"},{"key":"10.1016\/j.bpg.2019.101635_bib64","first-page":"288","article-title":"Epidemiology and clinical experience of chronic intestinal pseudo-obstruction in Japan: a nationwide epidemiologic survey","volume":"23","author":"Iida","year":"2013","journal-title":"J\u00a0Epidemiol"},{"key":"10.1016\/j.bpg.2019.101635_bib65","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s00439-002-0765-8","article-title":"SOX10 mutations in chronic intestinal pseudo-obstruction suggest a complex physiopathological mechanism","volume":"111","author":"Pingault","year":"2002","journal-title":"Hum Genet"},{"key":"10.1016\/j.bpg.2019.101635_bib66","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1053\/j.gastro.2012.08.045","article-title":"Segregation of a missense variant in enteric smooth muscle actin gamma-2 with autosomal dominant familial visceral myopathy","volume":"143","author":"Lehtonen","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib67","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1053\/j.gastro.2014.12.034","article-title":"Mutations in RAD21 disrupt regulation of APOB in patients with chronic intestinal pseudo-obstruction","volume":"148","author":"Bonora","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib68","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/ng.3113","article-title":"Mutations in SGOL1 cause a novel cohesinopathy affecting heart and gut rhythm","volume":"46","author":"Chetaille","year":"2014","journal-title":"Nat Genet"},{"key":"10.1016\/j.bpg.2019.101635_bib69","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1126\/science.283.5402.689","article-title":"Thymidine phosphorylase gene mutations in MNGIE, a human mitochondrial disorder","volume":"283","author":"Nishino","year":"1999","journal-title":"Science"},{"key":"10.1016\/j.bpg.2019.101635_bib70","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1038\/sj.ejhg.5201002","article-title":"Novel POLG mutations in progressive external ophthalmoplegia mimicking mitochondrial neurogastrointestinal encephalomyopathy","volume":"11","author":"Van Goethem","year":"2003","journal-title":"Eur J Hum Genet"},{"key":"10.1016\/j.bpg.2019.101635_bib71","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1002\/ajmg.a.30793","article-title":"Congenital idiopathic intestinal pseudo-obstruction and hydrocephalus with stenosis of the aqueduct of sylvius","volume":"130A","author":"Bott","year":"2004","journal-title":"Am J Med Genet"},{"key":"10.1016\/j.bpg.2019.101635_bib72","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1086\/513321","article-title":"Filamin A is mutated in X-linked chronic idiopathic intestinal pseudo-obstruction with central nervous system involvement","volume":"80","author":"Gargiulo","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.bpg.2019.101635_bib73","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1053\/j.gastro.2009.03.054","article-title":"Frequency of mitochondrial defects in patients with chronic intestinal pseudo-obstruction","volume":"137","author":"Amiot","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib74","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.3748\/wjg.v18.i33.4557","article-title":"Characteristics of intestinal pseudo-obstruction in patients with mitochondrial diseases","volume":"18","author":"Sekino","year":"2012","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib75","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1007\/s10620-018-4977-8","article-title":"Intestinal involvement in systemic sclerosis: a clinical review","volume":"63","author":"Sakkas","year":"2018","journal-title":"Dig Dis Sci"},{"key":"10.1016\/j.bpg.2019.101635_bib76","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/096120330000900104","article-title":"Intestinal pseudo-obstruction in systemic lupus erythematosus: an uncommon but important clinical manifestation","volume":"9","author":"Mok","year":"2000","journal-title":"Lupus"},{"key":"10.1016\/j.bpg.2019.101635_bib77","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1590\/S0037-86822004000300012","article-title":"Chagasic enteropathy","volume":"37","author":"Meneghelli","year":"2004","journal-title":"Rev Soc Bras Med Trop"},{"key":"10.1016\/j.bpg.2019.101635_bib78","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s40364-014-0023-y","article-title":"The great masquerader of malignancy: chronic intestinal pseudo-obstruction","volume":"2","author":"Taverna","year":"2014","journal-title":"Biomark Res"},{"key":"10.1016\/j.bpg.2019.101635_bib79","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1136\/jmg.29.11.791","article-title":"Intestinal pseudo-obstruction in myotonic dystrophy","volume":"29","author":"Brunner","year":"1992","journal-title":"J\u00a0Med Genet"},{"key":"10.1016\/j.bpg.2019.101635_bib80","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1179\/2295333714Y.0000000110","article-title":"A\u00a0case of delayed oxaliplatin-induced pseudo-obstruction: an atypical presentation of oxaliplatin neurotoxicity","volume":"70","author":"Vandamme","year":"2015","journal-title":"Acta Clin Belg"},{"key":"10.1016\/j.bpg.2019.101635_bib81","doi-asserted-by":"crossref","first-page":"e126","DOI":"10.1097\/MPH.0b013e3181d7742f","article-title":"Vincristine and intestinal pseudo-obstruction in children: report of 5 cases, literature review, and suggested management","volume":"32","author":"Diezi","year":"2010","journal-title":"J\u00a0Pediatr Hematol Oncol"},{"key":"10.1016\/j.bpg.2019.101635_bib82","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1097\/00003643-199805000-00022","article-title":"Intestinal pseudo-obstruction associated with oral morphine","volume":"15","author":"Murthy","year":"1998","journal-title":"Eur J Anaesthesiol"},{"key":"10.1016\/j.bpg.2019.101635_bib83","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.transproceed.2009.12.014","article-title":"Chronic intestinal pseudo-obstruction related to viral infections","volume":"42","author":"De Giorgio","year":"2010","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2019.101635_bib84","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1007\/s00401-009-0527-y","article-title":"Gastrointestinal neuromuscular pathology: guidelines for histological techniques and reporting on behalf of the Gastro 2009 International Working Group","volume":"118","author":"Knowles","year":"2009","journal-title":"Acta Neuropathol"},{"key":"10.1016\/j.bpg.2019.101635_bib85","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1136\/gut.2009.200444","article-title":"The london classification of gastrointestinal neuromuscular pathology: report on behalf of the gastro 2009 international working group","volume":"59","author":"Knowles","year":"2010","journal-title":"Gut"},{"key":"10.1016\/j.bpg.2019.101635_bib86","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1053\/gast.2002.37059","article-title":"Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome","volume":"123","author":"T\u00f6rnblom","year":"2002","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bpg.2019.101635_bib87","article-title":"Chronic intestinal pseudo-obstruction: progress in management?","volume":"29","author":"Di Nardo","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bpg.2019.101635_bib88","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1038\/ajg.2009.58","article-title":"Long-term outcome of chronic intestinal pseudo-obstruction adult patients requiring home parenteral nutrition","volume":"104","author":"Amiot","year":"2009","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib89","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.clnu.2017.04.013","article-title":"Clinical classification of adult patients with chronic intestinal failure due to benign disease: an international multicenter cross-sectional survey","volume":"37","author":"Pironi","year":"2018","journal-title":"Clin Nutr"},{"key":"10.1016\/j.bpg.2019.101635_bib90","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1053\/j.sempedsurg.2004.10.016","article-title":"Intestinal transplantation for total\/near-total aganglionosis and intestinal pseudo-obstruction","volume":"13","author":"Bond","year":"2004","journal-title":"Semin Pediatr Surg"},{"key":"10.1016\/j.bpg.2019.101635_bib91","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.transproceed.2004.03.004","article-title":"Italian guidelines for intestinal transplantation: potential candidates among the adult patients managed by a medical referral center for chronic intestinal failure","volume":"36","author":"Pironi","year":"2004","journal-title":"Transplant Proc"},{"key":"10.1016\/j.bpg.2019.101635_bib92","first-page":"2147","article-title":"The surgeon's role in the treatment of chronic intestinal pseudoobstruction","volume":"90","author":"Murr","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib93","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1097\/00004836-199906000-00005","article-title":"Nutritional management of chronic intestinal pseudo-obstruction","volume":"28","author":"Scolapio","year":"1999","journal-title":"J\u00a0Clin Gastroenterol"},{"key":"10.1016\/j.bpg.2019.101635_bib94","doi-asserted-by":"crossref","DOI":"10.1111\/nmo.13127","article-title":"Efficacy of percutaneous endoscopic gastro-jejunostomy (PEG-J) decompression therapy for patients with chronic intestinal pseudo-obstruction (CIPO)","volume":"29","author":"Ohkubo","year":"2017","journal-title":"Neurogastroenterol Motil"},{"key":"10.1016\/j.bpg.2019.101635_bib95","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.gtc.2017.09.005","article-title":"Nutritional interventions in chronic intestinal pseudoobstruction","volume":"47","author":"Kirby","year":"2018","journal-title":"Gastroenterol Clin N Am"},{"key":"10.1016\/j.bpg.2019.101635_bib96","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1111\/j.1365-2036.2004.01900.x","article-title":"Erythromycin for the treatment of chronic intestinal pseudo-obstruction: description of six cases with a positive response","volume":"19","author":"Emmanuel","year":"2004","journal-title":"Aliment Pharmacol Ther"},{"key":"10.1016\/j.bpg.2019.101635_bib97","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.amsu.2014.04.002","article-title":"Neostigmine for acute colonic pseudo-obstruction: a meta-analysis","volume":"3","author":"Valle","year":"2014","journal-title":"Ann Med Surg (Lond)."},{"key":"10.1016\/j.bpg.2019.101635_bib98","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1111\/j.1463-1318.2009.01838.x","article-title":"The efficacy of treatment of patients with severe constipation or recurrent pseudo-obstruction with pyridostigmine","volume":"12","author":"O'Dea","year":"2010","journal-title":"Colorectal Dis"},{"key":"10.1016\/j.bpg.2019.101635_bib99","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/j.1365-2036.2011.04907.x","article-title":"Randomised clinical trial: the efficacy of prucalopride in patients with chronic intestinal pseudo-obstruction--a double-blind, placebo-controlled, cross-over, multiple n\u00a0= 1 study","volume":"35","author":"Emmanuel","year":"2012","journal-title":"Aliment Pharmacol Ther"}],"container-title":["Best Practice & Research Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691819300381?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521691819300381?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T17:02:46Z","timestamp":1761498166000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521691819300381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":99,"alternative-id":["S1521691819300381"],"URL":"https:\/\/doi.org\/10.1016\/j.bpg.2019.101635","relation":{},"ISSN":["1521-6918"],"issn-type":[{"value":"1521-6918","type":"print"}],"subject":[],"published":{"date-parts":[[2019,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pseudo-obstruction, enteric dysmotility and irritable bowel syndrome","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Gastroenterology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpg.2019.101635","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"101635"}}